Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company, on Wednesday
announced a registered direct offering of 3,167,986 shares of its common stock
at a price of $0.40 each, for gross proceeds of about $1.26 million prior to
deduction of commissions and offering expenses. In a concurrent private
placement, Genprex agreed to issue unregistered warrants to purchase up to
3,167,986 shares to the investors in the registered direct offering. The
warrants, which have an exercise price of $0.46 per share, will be exercisable
six months from the issuance date and will expire after five years. The
warrants will be exercisable for 100% of shares purchased by each investor in
the registered direct offering. Additionally, Genprex agreed to decrease the
exercise price of 2,283,740 warrants held by the purchasers in the registered
direct offering to $0.46, which will be exercisable six months from the closing
of the offering and the expiration date will be extended to January 27, 2024.
Closing is anticipated to take place on or around November 25, 2019, subject to
the completion of customary closing conditions. Genprex plans to use the net
proceeds of the offering for working capital and general corporate purposes.
To view the full press release, visit http://ibn.fm/x6Wr0
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer patients based
upon a unique proprietary technology platform. Genprex’s platform technologies
are designed to administer cancer-fighting genes by encapsulating them into
nanoscale hollow spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express proteins that are
missing or found in low quantities. The company’s lead product candidate,
Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), has a
multimodal mechanism of action whereby it interrupts cell signaling pathways
that cause replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells, and
modulates the immune response against cancer cells. Oncoprex has also been
shown to block mechanisms that create drug resistance. For more information,
visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment